Jay S. Skyler

1978–2026 年に発表

95
論文数
19,540
被引用数
71
h 指数
92
i10 指数

被引用数

Jay S. Skyler の年別被引用数1979 年: 被引用 2 件1981 年: 被引用 1 件1982 年: 被引用 6 件1983 年: 被引用 4 件1984 年: 被引用 5 件1985 年: 被引用 1 件1986 年: 被引用 6 件1987 年: 被引用 11 件1988 年: 被引用 7 件1989 年: 被引用 14 件1990 年: 被引用 9 件1991 年: 被引用 17 件1992 年: 被引用 9 件1993 年: 被引用 11 件1994 年: 被引用 11 件1995 年: 被引用 11 件1996 年: 被引用 9 件1997 年: 被引用 17 件1998 年: 被引用 15 件1999 年: 被引用 11 件2000 年: 被引用 14 件2001 年: 被引用 36 件2002 年: 被引用 45 件2003 年: 被引用 44 件2004 年: 被引用 60 件2005 年: 被引用 59 件2006 年: 被引用 52 件2007 年: 被引用 68 件2008 年: 被引用 73 件2009 年: 被引用 65 件2010 年: 被引用 99 件2011 年: 被引用 79 件2012 年: 被引用 109 件2013 年: 被引用 150 件2014 年: 被引用 120 件2015 年: 被引用 149 件2016 年: 被引用 117 件2017 年: 被引用 131 件2018 年: 被引用 134 件2019 年: 被引用 506 件2020 年: 被引用 710 件2021 年: 被引用 696 件2022 年: 被引用 548 件2023 年: 被引用 499 件2024 年: 被引用 780 件2025 年: 被引用 481 件2026 年: 被引用 8 件1980 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,933 件、この内訳の 27.2%イギリス: 引用元論文 641 件、この内訳の 9%中国: 引用元論文 420 件、この内訳の 5.9%イタリア: 引用元論文 360 件、この内訳の 5.1%ドイツ: 引用元論文 347 件、この内訳の 4.9%カナダ: 引用元論文 299 件、この内訳の 4.2%オーストラリア: 引用元論文 259 件、この内訳の 3.7%スウェーデン: 引用元論文 214 件、この内訳の 3%インド: 引用元論文 164 件、この内訳の 2.3%デンマーク: 引用元論文 160 件、この内訳の 2.3%フランス: 引用元論文 155 件、この内訳の 2.2%オランダ: 引用元論文 145 件、この内訳の 2%
0%27.2%その他 28.2%

分野

  • Medicine59.1%
  • Biochemistry, Genetics and Molecular Biology30%
  • Immunology and Microbiology3.2%
  • Nursing1.9%
  • Health Professions1.4%
  • Neuroscience0.8%
  • その他3.6%

トピック

  • Diabetes and associated disorders12.6%
  • Diabetes Management and Research12.5%
  • Pancreatic function and diabetes10.8%
  • Diabetes Treatment and Management5.3%
  • COVID-19 Clinical Research Studies2.5%
  • Diabetes, Cardiovascular Risks, and Lipoproteins2.3%
  • その他54%

共著者

全論文

検索で開く
  1. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 1,112

  2. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

    著者: , , , , , , , , , , , , , , , - Diabetes Care 2015 被引用: 1,148

  3. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    著者: , , , , , , , , , , , , , - Diabetes Care 2021 被引用: 658

  4. Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 被引用: 1,073

  5. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

    著者: , , , , , , , , , , , , , , , , - Diabetes 2016 被引用: 824

  6. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet 2011 被引用: 601

  7. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

    著者: , , , , , , , , , , - Diabetes Care 2018 被引用: 357

  8. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2023 被引用: 96

  9. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Diabetes Care 2019 被引用: 356

  10. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Mikael Knip, J. Krischer, Åke Lernmark, W. Moore, Antoinette Moran, Andrew J. Muir, J. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, W. J. Russell, Lisa M. Spain, Desmond Schatz, Jay M. Sosenko, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Mark S. Anderson, Peter A. Antinozzi, Christophe Benoıst, J.J. Blum, Kasia Bourcier, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, Catherine C. Cowie, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, L. Harrison, Bernhard J. Hering, Richard A. Insel, Sabine D. Jordan, Francine Kaufman, Tom Kay, Norma S. Kenyon, R. Klines, John M. Lachin, Ellen Leschek, Jeff Mahon, Jennifer B. Marks, Roshanak Monzavi, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, A. Pugliese, John A. Ridge, Bart O. Roep, Maria Grazia Roncarolo, Peter J. Savage, Olli Simell, R S Sherwin, Mark Siegelman, Jay S. Skyler, Andrea K. Steck, James W. Thomas, Massimo Trucco ほか 212 名 - Diabetes Care 2018 被引用: 180

  11. B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results

    著者: , , , , , , , , , , , , , , , , - Diabetes Care 2013 被引用: 282

  12. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Mandrup‐Poulsen - The Lancet 2013 被引用: 354

  13. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alberto Pugliese, P. Raskin, Henry Rodriguez, Bart O. Roep, William E. Russell, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Christophe Benoıst, J.J. Blum, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, Bernhard J. Hering, Francine Kaufman, Ellen Leschek, J. Mahon, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, Maria Grazia Roncarolo, Olli Simell, Robert Sherwin, Mark Siegelman, Andrea K. Steck, James W. Thomas, Massimo Trucco, J. Richard Wagner, Carla J. Greenbaum, Katarzyna Bourcier, Richard A. Insel, Jeffrey P. Krischer, Ellen Leschek, Lisa Rafkin, Lisa M. Spain, Catherine C. Cowie, Mary A. Foulkes, Heidi Krause‐Steinrauf, John M. Lachin, Saúl Malozowski, John Peyman, J P Ridge, Peter J. Savage, Jay S. Skyler, Stephanie J. Zafonte, Norma S. Kenyon, Irene Santiago, Jay M. Sosenko, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, Brian N. Bundy, Cristina Burroughs, David Cuthbertson, Mary Deemer, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson ほか 1,520 名 - Diabetes Care 2018 被引用: 169

  14. Novel therapies with precision mechanisms for type 2 diabetes mellitus

    著者: , , - Nature Reviews Endocrinology 2021 被引用: 131

  15. COVID-19 and metabolic disease: mechanisms and clinical management

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giatgen A. Spinas, Felix Beuschlein, Rüdiger Landgraf, Francesco Rubino, Geltrude Mingrone, Stefan R. Bornstein - The Lancet Diabetes & Endocrinology 2021 被引用: 250

  16. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , P. J. Bingley, Emanuele Bosi, Jane H. Buckner, Mark A. Clements, Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter Gottlieb, Kevan C. Herold, Mikael Knip, Jeffrey P. Krischer, Åke Lernmark, Wayne D. Moore, Antoinette Moran, Andrew J. Muir, Jerry P. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, William E. Russell, Desmond A. Schatz, Jay M. Sosenko, Lisa M. Spain, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette G. Ziegler, Mark S. Anderson, Peter A. Antinozzi, Richard A. Insel, Thomas W. H. Kay, Jennifer B. Marks, Alberto Pugliese, Bart O. Roep, Jay S. Skyler, Jorma Toppari, Carla J. Greenbaum, Jeffrey P. Krischer, Ellen Leschek, Lisa Spain, Katarzyna Bourcier, Richard A. Insel, J P Ridge, Jay S. Skyler, Carla J. Greenbaum, Lisa Rafkin, Jay M. Sosenko, Jay S. Skyler, Irene Santiago, Jeffrey P. Krischer, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Ilma Asif, Jenna Bjellquist, Matthew Boonstra, Cristina Burroughs, Mario Cleves, David Cuthbertson, Meagan DeSalvatore, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson, Susan Geyer ほか 178 名 - Diabetes 2019 被引用: 131

  17. Fall in C-Peptide During First 2 Years From Diagnosis

    著者: , , , , , , , , , , , , , - Diabetes 2012 被引用: 320

  18. Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heba M. Ismail, Laura M. Jacobsen, Suzanne Bennett Johnson, Leslie E. Kolb, Olga Kordonouri, Karin Lange, Robert W. Lash, Åke Lernmark, Ingrid Libman, Markus Lundgren, David M. Maahs, M. Loredana Marcovecchio, Chantal Mathieu, Kellee M. Miller, Holly K. O’Donnell, Tal Oron, Shivajirao P. Patil, Rodica Pop‐Busui, Marian Rewers, Stephen S. Rich, Desmond Schatz, Rifka Schulman‐Rosenbaum, Kimber M. Simmons, Emily K. Sims, Jay S. Skyler, Laura Smith, Cate Speake, Andrea K. Steck, Nicholas Thomas, Ksenia N. Tonyushkina, Riitta Veijola, John M. Wentworth, Diane K. Wherrett, Jamie Wood, Anette‐Gabriele Ziegler, Linda A. DiMeglio - Diabetes Care 2024 被引用: 68

  19. Practical recommendations for the management of diabetes in patients with COVID-19

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2020 被引用: 993

  20. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes

    著者: , , , , - JAMA 2017 被引用: 203

  21. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2011 被引用: 369

  22. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum

    著者: , , , , , , , , , , , , - Diabetes Care 2017 被引用: 369

  23. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

    著者: , , , , , , , , , , , , , , , , , - Diabetes Research and Clinical Practice 2023 被引用: 57

  24. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

    著者: , , , , , , , , , , - Diabetes 2004 被引用: 484